C Lance Cowey

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. pmc New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
    C Lance Cowey
    Baylor Sammons Cancer Center Texas Oncology, PA, GU Oncology Program, Dallas
    Onco Targets Ther 3:147-55. 2010
  2. pmc Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
    C Lance Cowey
    Baylor Sammons Cancer Center, Texas Oncology, PA, US Oncology Research, Dallas, TX, USA
    Drug Des Devel Ther 7:519-27. 2013
  3. ncbi request reprint Molecularly targeted agents for renal cell carcinoma: the next generation
    C Lance Cowey
    Genitourinary Oncology and Melanoma Program, Baylor University Medical Center, Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Adv Hematol Oncol 8:357-60, 361-4. 2010
  4. doi request reprint Sequential use of targeted agents in the treatment of renal cell carcinoma
    Thomas E Hutson
    Baylor University Medical Center, Dallas, TX 75246, United States
    Crit Rev Oncol Hematol 77:48-62. 2011
  5. doi request reprint Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Clin Genitourin Cancer 10:1-5. 2012

Detail Information

Publications6

  1. pmc New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
    C Lance Cowey
    Baylor Sammons Cancer Center Texas Oncology, PA, GU Oncology Program, Dallas
    Onco Targets Ther 3:147-55. 2010
    ..In this review, the outcomes of the clinical testing of pazopanib are discussed, as well as a perspective on the placement of pazopanib among other approved agents...
  2. pmc Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
    C Lance Cowey
    Baylor Sammons Cancer Center, Texas Oncology, PA, US Oncology Research, Dallas, TX, USA
    Drug Des Devel Ther 7:519-27. 2013
    ..Also, the potential placement of tivozanib among currently US Food and Drug Administration approved agents for advanced RCC will be discussed. ..
  3. ncbi request reprint Molecularly targeted agents for renal cell carcinoma: the next generation
    C Lance Cowey
    Genitourinary Oncology and Melanoma Program, Baylor University Medical Center, Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Adv Hematol Oncol 8:357-60, 361-4. 2010
    ..The development of optimal sequencing and combinations of these drugs is important to improving patient outcomes and overcoming resistance mechanisms...
  4. doi request reprint Sequential use of targeted agents in the treatment of renal cell carcinoma
    Thomas E Hutson
    Baylor University Medical Center, Dallas, TX 75246, United States
    Crit Rev Oncol Hematol 77:48-62. 2011
    ..The current evidence supporting sequential use of targeted agents in RCC is presented in this review...
  5. doi request reprint Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Clin Genitourin Cancer 10:1-5. 2012
    ..The frequency of cisplatin-based chemotherapy administration in patients with advanced UC in community-based cancer centers is unknown...